Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TAK-816 in Healthy Infants
NCT02074345Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VaxemHIB in Haemophilus influenzae type b infection (Hib), sponsored by Takeda. Started Mar 2014; status: completed.
02
Drugs
VaxemHIB
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT02074345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074345.